A man with hypophosphataemia [PDF]
BMJ, 2011 Case report; A section on BMJ, 2011, v.
Kung, AW +5 more
core +5 more sources
Understanding and Managing Infusion Reactions and Hypophosphataemia With Intravenous Iron—A Nurses' Consensus Paper [PDF]
Nursing OpenAim To provide evidence‐based guidance on practical aspects and potential safety concerns (infusion reactions and hypophosphataemia) related to the use of intravenous iron from a nursing perspective. Design A modified Delphi consensus method.
Aileen Fraser +5 more
doaj +2 more sources
Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials [PDF]
ESC Heart Failure, 2023 Aims Iron deficiency is a common finding among patients with heart failure (HF) and is associated with adverse outcomes, including decreased quality of life, increased risk of hospitalization, and decreased survival.
Giuseppe MC Rosano +2 more
doaj +2 more sources
Treatment-resistant hypophosphataemia after ferric carboxymaltose: expanding the spectrum of 6H syndrome (hypophosphataemia, hyperphosphaturia, hypovitaminosis D, hypocalcaemia, secondary hyperparathyroidism, high fibroblast growth factor-23) [PDF]
European Journal of Case Reports in Internal MedicineBackground: Ferric carboxymaltose (FCM) is widely used to treat iron deficiency anaemia (IDA), particularly in patients with gastrointestinal disease who are intolerant of oral iron. While generally well tolerated, FCM is increasingly recognised to cause
Luqmaan Rashid
doaj +2 more sources
Severe hypercalcaemia and hypophosphataemia with an optimised preterm parenteral nutrition formulation in two epochs of differing phosphate supplementation [PDF]
Archives of Disease in Childhood: Fetal and Neonatal Edition, 2017 Objective: To compare in two epochs of differing phosphate provision serum calcium, phosphate, potassium, and sodium concentrations and the frequency of abnormality of these electrolytes and of sepsis in preterm infants who received an optimised higher ...
Susan Stirling, Paul Clarke
exaly +2 more sources
RMD Open, 2023 Objectives To report the impact of continued burosumab treatment on clinical laboratory tests of efficacy, patient-reported outcomes (PROs) and ambulatory function in adults with X-linked hypophosphataemia who continued from a 96-week phase 3 study into ...
Peter Kamenický +2 more
exaly +3 more sources
Improvements with burosumab treatment in an early access programme for adults with X-linked hypophosphataemia: A case series of three patients [PDF]
Bone ReportsX-linked hypophosphataemia (XLH) is a life-long phosphate-wasting disorder that causes skeletal deformities, pain, stiffness, and fatigue and impairs quality of life. Burosumab was approved for use in adults in 2020.
Julia Day +2 more
doaj +2 more sources
Drugs in Context, 2021 Third-generation intravenous (i.v.) iron preparations are safe and efficacious and are increasingly used in the treatment of iron-deficiency anaemia.
Xenophon Kassianides, Sunil Bhandari
doaj +1 more source
Clinical factors associated with severe hypophosphataemia after kidney transplant
BMC Nephrology, 2021 Background The mechanism by which hypophosphataemia develops following kidney transplantation remains debated, and limited research is available regarding risk factors. This study aimed to assess the association between recipient and donor variables, and
Maximilian R. Ralston +3 more
doaj +1 more source
Endokrynologia Polska, 2021 INTRODUCTION: X-linked hypophosphataemic rickets (XLHR) is the most common form of hypophosphataemic rickets (HR), which is caused by mutations in the PHEX gene.
Monika Obara-Moszynska +5 more
doaj +1 more source